You are now leaving www.klisyrihcp.com

You are now leaving KlisyriHCP.com and will be directed to an independent, third-party website. The Privacy Policy and the Terms of Use of the destination website will apply.

OK

What To Expect With KLISYRI®

Helping Patients Understand What To Expect From Their Treatment

Man talking with his doctor
Not an actual patient.

What To Expect: Results

teal bullet point

Although KLISYRI® is a treatment regimen for only 5 days, topical AK treatments still take time

teal bullet point

Let patients know that, with KLISYRI®, complete AK clearance was achieved in a majority of patients at day 571

See more study results for KLISYRI®

triangle icon

What To Expect:
Safety and tolerability

teal bullet point

Topical treatments are often associated with local skin reactions and other adverse events, and may take several days or weeks to resolve2

teal bullet point

Let patients know that the most common side effects of KLISYRI® included itching or pain in the treatment area1

See more about the safety and tolerability of KLISYRI®

triangle icon

What To Expect:
Dosing and Administration

teal bullet point

Tell patients that KLISYRI® is the shortest topical Rx treatment for AK available today, and that KLISYRI® SHOULD be used for only 5 consecutive days1

teal bullet point

If you are giving patients a starter sample, instruct them to use the sample only if they are picking up their full 5-day prescription the very next day

teal bullet point

Because KLISYRI® prescription packs contain 5 packets of medication, patients who receive a starter sample will have an extra packet and SHOULD be told to use 5 packets ONLY

PLEASE NOTE: the KLISYRI® prescription pack contains 5 packets of medication. Patients who receive a sample packet may inadvertently use a total of 6 packets instead of the prescribed 5. Please advise patients to use a total of 5 packets for 5 consecutive days.

Woman talking with her doctor
Not an actual patient.

What To Expect: Savings and Support

teal bullet point

Savings and support can help ensure patients fill and continue to take their prescription2

teal bullet point

Let patients know that KLISYRI® offers cost savings and support for eligible patients*

teal bullet point

Check with your KLISYRI® network specialty pharmacy to compare out-of-pocket costs

See more about patient savings through Almirall Advantage

triangle icon

*

Eligible patients with commercial (nongovernmental) insurance only. Terms and conditions may apply.
AK: actinic keratosis.

Important Safety Information

Indication

KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

Important Safety Information

Warnings and Precautions

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.

Adverse Reactions

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com

Important Safety Information

Indication

KLISYRI is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

Important Safety Information

Warnings and Precautions

Ophthalmic Adverse Reactions

KLISYRI may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.

Local Skin Reactions

Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of KLISYRI. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of KLISYRI is more likely to result in irritation.

Adverse Reactions

The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain.

Please see full Prescribing Information.

To report an adverse event or product complaint, call or email: Medical Affairs and Customer Relations • Phone: 1-866-665-2782 • Fax: 510-595-8183 • Email: almirallmc@eversana.com

References:

1. KLISYRI [package insert]. Exton, PA: Almirall, LLC, 2020. 2. Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017;32(suppl 2):17-20.

Almirall logo

KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2005-2021. All Rights Reserved. Almirall, LLC, Exton, PA 19341 US-TIRBA-2100057 02/2021

Klisyri logo

Sign Up

Information Request

Qualified U.S. healthcare professionals who are practicing medicine in the U.S. are invited to register, should they wish to receive information about KLISYRI®.

Terms and Conditions

Your submission of this Information Request form constitutes your specific request to receive ongoing email communications, including marketing communications and messages, from KLISYRI® and Almirall, LLC. You may opt out from such email communication at any time by following the "Unsubscribe" link and/or instructions included in the confirmation email you will receive as a result of this request.

By submission of this form, you affirm that you are a licensed healthcare professional eligible to practice in at least one state in the U.S. By submission of this form, you further agree to the terms and conditions set forth in the Almirall, LLC Privacy Policy page, available by clicking on the link at the bottom of this page.

*Required fields.
Submitting...

KLISYRI® is a registered trademark of Almirall, LLC. © Copyright 2005-2021. All Rights Reserved. Almirall, LLC, Exton, PA 19341 US-TIRBA-2100057 02/2021

Klisyri logo

Thank You For Signing Up!

You are now enrolled to receive news and updates about KLISYRI® (tirbanibulin) ointment. Please look for a welcome email that will be sent to .